MannKind Corporation (MNKD) News: Healthcare Conference, Executives, FAQ list & More

Editor’s Note:  MannKind Corporation (NASDAQ:MNKD)

MannKind Corporation to Present at Morgan Stanley Global Healthcare Conference (Market Watch)
MannKind Corporation, focused on discovering, developing and commercializing treatments for diabetes, announced today that it will present at The Morgan Stanley Global Healthcare Conference on Tuesday, September 10, 2013 at 3:30 PM (ET) at the Grand Hyatt Hotel in New York City.

MannKind Corporation (NASDAQ:MNKD)

MannKind Talks Down Insider Selling While Executives Sell Shares (The Street)
Two MannKind Corporation (NASDAQ:MNKD) executives sold company stock on the very same day MannKind tried to assure shareholders that key officers still had confidence in the company and were not selling stock. MannKind vice president and general counsel David Thomson and Corporate Vice President Juergen Martens sold 19,000 and 20,000 Mannkind shares, respectively, on Aug. 26., according to regulatory filings released Wednesday night.

MannKind Corporation (NASDAQ:MNKD)’s VP offloads 20,000 shares (GDP Insider)
In a transaction that was dated 26 August, MannKind Corporation (NASDAQ:MNKD)’s vice-president, Juergen Martens off-loaded 20,000 shares of the company in the open market. The shares were sold at an average-price of $5.52 and the total transaction value was $110,400.00. Post completion of this transaction, the VP now directly-owns 136,016 shares in MNKD. This sale was disclosed in an SEC filing.

MannKind addresses critics with FAQ list (Seeking Alpha)
Shares of MannKind Corporation (NASDAQ:MNKD) rise 4.3% premarket apparently in response to an SEC filing (8-K) which announces the publication of a series of FAQs (regarding the Affinity trial results) and responses from the company.MNKD addresses the perceived discrepancy between the 0.4% change in HbA1c observed in Affinity 2 and the 0.5% change the original study design appeared to have called for the demonstrate superiority. There’s nothing new here. The company says the 0.5% figure was related to the design of the trial and that the results were “extremely significant” — that’s the same thing they said on the conference call.

Is This a MannKind Killer? (Daily Finance)
Talk to MannKind Corporation (NASDAQ:MNKD) bulls, and you’ll hear two reasons why its insulin Afrezza is the best thing since sliced bread. The drug more closely mimics how the body secretes insulin after a meal to lower blood sugar, doing its job and leaving the bloodstream quickly. Since it doesn’t stick around as long as injected fast-acting insulins such as Eli Lilly’s Humalog or Novo Nordisk’s NovoLog, there’s less of a risk of hypoglycemia, or low blood sugar levels. Afrezza is inhaled rather than injected, allowing patients to avoid needles.